Daiichi Sankyo/AstraZeneca (AZN.US) has received approval for another new indication of its blockbuster ADC drug "Dsuvia" in China.

According to Zhitong Finance APP, on August 12, Daiichi Sankyo announced that a new indication for its blockbuster ADC drug "Trastuzumab Deruxtecan," developed in collaboration with AstraZeneca, has been approved for market launch. The indication is for first-line treatment in adult patients with unresectable or metastatic HER2-positive breast cancer in combination with Pertuzumab.